Anemia, Sickle Cell Clinical Trial
To determine the natural history of sickle cell disease from birth to death in order to identify those factors contributing to the morbidity and mortality of the disease.
BACKGROUND:
Sickle cell anemia (Hb SS) and related hemoglobinopathies involving sickle hemoglobin (HbS)
had been recognized for many years and numerous clinical and laboratory manifestations had
been described. However, the clinical course of sickle cell disease was poorly documented.
The ability to establish concrete interrelationships among signs, symptoms and laboratory
test results was complicated by the complexity of the interaction of basic disease processes
with other health related events.
Comprehensive evaluations of the clinical status of patients were usually carried out only
during hospitalizations for 'crises' or other acute illnesses. Because of this inconsistent
nature of the doctor/patient relationships, methods of periodic recording of the patient's
status needed to be established. Further, the obtaining of comprehensive laboratory data was
necessary during periods of apparent clinical remissions as well as hospitalizations. A well
designed, statistically valid, longitudinal study could make a significant contribution to a
better understanding of sickle cell disease. Information was particularly lacking on the
clinical course starting at birth. Criteria needed to be formulated that could establish
classifications of organ involvement and severity of the disease processes. Such
classifications could ultimately be used in establishing the need for and evaluating the
efficacy of proposed therapies.
The source of the idea for the study dates back to 1971 when the Hematology Study Section
recommended in a position paper a study on the natural history of sickle cell disease. The
Hemolytic Disease Study Group of the Division of Blood Diseases and Resources developed a
detailed protocol in 1973. The National Sickle Cell Disease Advisory Committee endorsed the
idea in 1975. In April 1976, the Red Cell Working Group of the Blood Diseases and Resources
Advisory Committee recommended initiating the study. The National Heart, Lung, and Blood
Advisory Council approved the initiative in December 1976.
Phase I, the Planning Phase, began in 1977. The protocols and Manual of Operations were
developed in this phase. Phase II, the Enrollment Phase, began in March 1979 and ended in
March 1981, except for infants younger than 6 months of age, who continued to be enrolled
after March 1981. In 1983 the study was extended for an additional five years through 1988.
Beginning in 1989, as a separate initiative, the study follows selected patient groups from
the original study for an additional five years. The selected groups include the newborn
cohort and patients surviving beyond age 35.
In 1981, the NHLBI offered a special competition for the evaluation of cardiac function in
sickle cell disease patients who were enrolled in the cooperative study of sickle cell
disease. The original general study protocol required assessment of the lungs, spleen,
kidneys, eyes, and liver but not the heart. The cardiac function study objectives were: to
determine cardiac function in a cross-section of sickle cell patients participating in the
larger study; to determine the incidence, prevalence, and onset of cardiac impairment; and
to assess changes in cardiac function and correlate the observed changes with other clinical
data. A total of 300 patients had an entry cardiac evaluation in the third year of the study
(June 1, 1981 through November 30, 1981) and an exit cardiac evaluation two years later in
the fifth year of the study which was conducted at four centers.
Twelve cooperative study of sickle cell disease centers and eleven other clinical
institutions initiated the Penicillin Prophylaxis in Sickle Cell Disease (PROPS I) clinical
trial in August 1983. The objective of the trial was to determine whether the regular daily
administration of oral penicillin would reduce the incidence of documented infection due to
Streptococcus pneumoniae in children aged 3 months to 3 years with sickle cell anemia. The
trial was scheduled to end in February 1986 but was terminated eight months early, after an
average of 15 months of follow-up, when an 84 percent reduction in the incidence of
infection was observed in the penicillin group as compared to the placebo group.
DESIGN NARRATIVE:
Baseline data were collected, including demographic and past medical history and clinical
and laboratory information. Stabilized patients were re-examined every six months. Newborns
and young infants were re-examined every two to three months. Organ damage to the lungs,
spleen, kidneys, eyes, and liver was measured at specific entry and exit points to provide
longitudinal data. Data was also gathered on all acute and chronic complications related to
sickle cell disease to provide cross-sectional evaluation.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06078696 -
Siplizumab for Sickle Cell Disease Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02561312 -
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
|
||
Completed |
NCT00890396 -
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
|
||
Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Recruiting |
NCT02286154 -
Therapeutic Response Evaluation and Adherence Trial (TREAT)
|
N/A | |
Completed |
NCT02857023 -
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
|
N/A | |
Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
Terminated |
NCT00122980 -
Stroke With Transfusions Changing to Hydroxyurea
|
Phase 3 | |
Completed |
NCT00246077 -
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
|
N/A | |
Completed |
NCT00094887 -
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
|
Phase 2 | |
Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
Terminated |
NCT04091737 -
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
|
Phase 1 | |
Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
Recruiting |
NCT04351698 -
SMILES: Study of Montelukast in Sickle Cell Disease
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06290401 -
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
|
Phase 2 | |
Recruiting |
NCT05087303 -
Telemedicine for Children With Sickle Cell Disease
|
N/A |